139 related articles for article (PubMed ID: 26688384)
21. Healthcare resource utilization in patients with myeloproliferative neoplasms: A Danish nationwide matched cohort study.
Christensen SF; Svingel LS; Kjaersgaard A; Stenling A; Darvalics B; Paulsson B; Andersen CL; Christiansen CF; Stentoft J; Starklint J; Severinsen MT; Clausen MB; Hilsøe MH; Hasselbalch HC; Frederiksen H; Mikkelsen EM; Bak M
Eur J Haematol; 2022 Nov; 109(5):526-541. PubMed ID: 35900040
[TBL] [Abstract][Full Text] [Related]
22. [Choice of therapy and overall survival in patients with chronic myeloproliferative diseases].
Rukavitsyn OA; Pop VP; Seriakov AP
Vopr Onkol; 2004; 50(4):435-9. PubMed ID: 15605767
[TBL] [Abstract][Full Text] [Related]
23. The management of elderly patients with myeloproliferative disorders.
Tura S
Hematol Oncol; 1993; 11 Suppl 1():39-41. PubMed ID: 8486340
[No Abstract] [Full Text] [Related]
24. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia.
Johansson P
Semin Thromb Hemost; 2006 Apr; 32(3):171-3. PubMed ID: 16673273
[TBL] [Abstract][Full Text] [Related]
25. The expression of Death Inducer-Obliterator (DIDO) variants in Myeloproliferative Neoplasms.
Berzoti-Coelho MG; Ferreira AF; de Souza Nunes N; Pinto MT; Júnior MC; Simões BP; Martínez-A C; Souto EX; Panepucci RA; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2016 Jul; 59():25-30. PubMed ID: 27282563
[TBL] [Abstract][Full Text] [Related]
26. Leukemic transformation in patients with myeloproliferative neoplasms: a population-based retrospective study.
Shrestha R; Giri S; Armitage JO; Bhatt VR
Future Oncol; 2017 Jun; 13(14):1239-1246. PubMed ID: 28589759
[TBL] [Abstract][Full Text] [Related]
27. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.
Passamonti F; Rumi E; Pungolino E; Malabarba L; Bertazzoni P; Valentini M; Orlandi E; Arcaini L; Brusamolino E; Pascutto C; Cazzola M; Morra E; Lazzarino M
Am J Med; 2004 Nov; 117(10):755-61. PubMed ID: 15541325
[TBL] [Abstract][Full Text] [Related]
28. [Epidemiologic features of Philadelphia-negative chronic myeloproliferative disorders in Szabolcs-Szatmár-Bereg county, Hungary. Analysis of data of a 33-year period].
Jakó J; Szerafin L
Orv Hetil; 2017 Apr; 158(15):572-578. PubMed ID: 28393599
[TBL] [Abstract][Full Text] [Related]
29. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.
Baxter EJ; Scott LM; Campbell PJ; East C; Fourouclas N; Swanton S; Vassiliou GS; Bench AJ; Boyd EM; Curtin N; Scott MA; Erber WN; Green AR;
Lancet; 2005 Mar 19-25; 365(9464):1054-61. PubMed ID: 15781101
[TBL] [Abstract][Full Text] [Related]
30. Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia.
Alvarez-Larrán A; Senín A; Fernández-Rodríguez C; Pereira A; Arellano-Rodrigo E; Gómez M; Ferrer-Marin F; Martínez-López J; Camacho L; Colomer D; Angona A; Navarro B; Cervantes F; Besses C; Bellosillo B; Hernández-Boluda JC
Br J Haematol; 2017 Sep; 178(5):764-771. PubMed ID: 28542718
[TBL] [Abstract][Full Text] [Related]
31. [Use of interferon in the treatment of chronic myeloproliferative disorders].
Robak T
Acta Haematol Pol; 1992; 23(2 Suppl 1):30-7. PubMed ID: 1488870
[TBL] [Abstract][Full Text] [Related]
32. [Chronic myeloproliferative diseases].
Sréter L
Orv Hetil; 1998 Jul; 139(30):1779-83. PubMed ID: 9718944
[TBL] [Abstract][Full Text] [Related]
33. The chronic myeloproliferative disorders: an historical perspective.
Steensma DP
Curr Hematol Rep; 2003 May; 2(3):221-30. PubMed ID: 12901343
[TBL] [Abstract][Full Text] [Related]
34. [Research progress of myeloproliferative neoplasms].
He HJ; Chen BA
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Feb; 23(1):278-84. PubMed ID: 25687088
[TBL] [Abstract][Full Text] [Related]
35. Molecular genetic evaluation of myeloproliferative neoplasms.
Azzato EM; Bagg A
Int J Lab Hematol; 2015 May; 37 Suppl 1():61-71. PubMed ID: 25976962
[TBL] [Abstract][Full Text] [Related]
36. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders.
Rozman C; Giralt M; Feliu E; Rubio D; Cortés MT
Cancer; 1991 May; 67(10):2658-63. PubMed ID: 2015567
[TBL] [Abstract][Full Text] [Related]
37. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.
Passamonti F; Giorgino T; Mora B; Guglielmelli P; Rumi E; Maffioli M; Rambaldi A; Caramella M; Komrokji R; Gotlib J; Kiladjian JJ; Cervantes F; Devos T; Palandri F; De Stefano V; Ruggeri M; Silver RT; Benevolo G; Albano F; Caramazza D; Merli M; Pietra D; Casalone R; Rotunno G; Barbui T; Cazzola M; Vannucchi AM
Leukemia; 2017 Dec; 31(12):2726-2731. PubMed ID: 28561069
[TBL] [Abstract][Full Text] [Related]
38. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
Brière J
Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
[TBL] [Abstract][Full Text] [Related]
39. Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders.
Bock O; Schlué J; Mengel M; Büsche G; Serinsöz E; Kreipe H
J Pathol; 2004 May; 203(1):609-15. PubMed ID: 15095485
[TBL] [Abstract][Full Text] [Related]
40. [Essential thrombocythaemia and other myeloproliferative disorders with thrombocythaemia treated with Thromboreductin. A report from the database of register for the 1st quarter of 2010].
Penka M; Schwarz J; Ovesná P; Hlusí A; Korístek Z; Doubek M; Dulícek P; Pospísilová D; Kissová J; Buliková A; Pavlík T;
Vnitr Lek; 2010 Jun; 56(6):503-12. PubMed ID: 20681462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]